Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Dextroamphetamine has a high potential for abuse due to its dopaminergic rewarding properties affecting the mesocorticolimbic circuit. Recreational use frequently leads to compulsive use patterns, with individuals who self-administer high doses having high risk of developing addiction through ΔFosB overexpression in the nucleus accumbens. Therapeutic use at prescribed doses carries substantially lower addiction risk and may actually reduce risk of developing substance use disorders when used for ADHD treatment beginning in childhood.
Physical dependence develops with chronic heavy use. When chronic high-dose users abruptly discontinue, approximately 88% experience a time-limited withdrawal syndrome within 24 hours of their last dose, persisting 3-4 weeks with a marked crash phase during the first week. Withdrawal symptoms include anxiety, drug craving, depressed mood, fatigue, increased appetite, movement changes, lack of motivation, and sleep disturbances. Discontinuation at therapeutic doses does not typically produce withdrawal symptoms.
Overdose is rarely fatal with appropriate care. Tolerant individuals have been documented taking as much as 5 grams in a day (roughly 100 times the maximum therapeutic dose). Fatal amphetamine poisoning typically involves convulsions and coma. In 2013, overdose on amphetamine, methamphetamine, and related compounds resulted in an estimated 3,788 deaths worldwide.
Acute cardiovascular effects including hypertension, hypotension, tachycardia, arrhythmias, and Raynaud's phenomenon occur during use; however, large studies including a 2022 meta-analysis of nearly four million participants found no association between therapeutic amphetamine use and serious cardiovascular events (sudden death, heart attack, stroke) in any age group.
High doses in animal models cause dopaminergic neurotoxicity characterized by dopamine terminal degeneration and reduced transporter function; however, there is no evidence of direct neurotoxicity in humans at therapeutic doses, and long-term pharmaceutical use in ADHD patients appears to improve brain development and nerve growth.
Rapid muscle breakdown (rhabdomyolysis) may occur at excessive doses significantly exceeding typical recreational or therapeutic ranges.
Teratogenic and embryotoxic effects observed in mice at 41 times the maximum human dose but not in rat or rabbit studies; therapeutic use in humans does not appear to cause developmental abnormalities, though abuse during pregnancy poses fetal risks.
Stimulant psychosis involving delusions, paranoia, and hallucinations can occur in heavy recreational users. Approximately 5-15% of users who develop amphetamine psychosis fail to recover completely. Psychosis rarely arises from therapeutic use, though individuals with pre-existing psychotic disorders may be at risk even at therapeutic doses. Antipsychotic medications have been shown to effectively resolve symptoms of acute amphetamine psychosis.
Amphetamine may reduce seizure threshold as a side effect. Convulsions are primarily associated with severe overdose and fatal poisoning rather than typical use. Contraindicated in individuals with seizure disorders.
Racemic amphetamine was first synthesized in Berlin in 1887 by the Romanian chemist Lazăr Edeleanu, who prepared the compound under the chemical name "phenylisopropylamine." The substance remained relatively obscure for several decades until the pharmaceutical company Smith, Kline & French began…
United Nations Convention on Psychotropic Substances 1971 (Schedule II)
Classified as a controlled drug under the Poisons Standard. Available by prescription for therapeutic purposes but subject to strict dispensing and record-keeping requirements.
Controlled as a Class A3 psychoactive substance under national pharmaceutical legislation, indicating recognized abuse potential with some therapeutic application.
Classified as a narcotic substance as an isomer of amphetamine. Possession, purchase, sale, and manufacture are prohibited. Notably, it is not available by medical prescription in France, unlike in many other jurisdictions.
Controlled as a hard drug under List I of the Opium Act. Unauthorized possession, distribution, and production carry criminal penalties.
Controlled substance with restricted prescribing authority. Only physicians with specialist qualifications in child and adolescent psychiatry, adult psychiatry, forensic psychiatry, neurology, or child and adolescent neurology with habilitation may prescribe it.
Controlled under Schedule II of the Controlled Substances Act, recognized as having substantial abuse potential alongside accepted medical applications. Marketed under trade names including Dexedrine and Zenzedi for treatment of ADHD and narcolepsy.
Prohibited under the Suchtmittelgesetz (Narcotics Act). Possession, production, and sale are illegal without specific authorization.
Controlled under Schedule I of the Controlled Drugs and Substances Act. Available for medical use by prescription but subject to strict regulatory oversight.
Controlled under Anlage III of the Betäubungsmittelgesetz (Narcotics Act), indicating a prescription-capable narcotic. Can only be dispensed using a special narcotic prescription form (Betäubungsmittelrezept).
Completely banned including for medical purposes, in strict compliance with United Nations Convention obligations. No therapeutic exemptions are granted.
Amphetamine and its isomers are controlled under the Misuse of Drugs Act 1971. Available by prescription for medical conditions but unauthorized possession and supply constitute criminal offenses.
10 sources cited